Perrigo Company plc is a global leader in self-brand health products, headquartered in Dublin, Ireland, and publicly traded on the New York Stock Exchange under ticker PRGO. The company operates across more than 40 countries with an integrated business model spanning production, research and development, branding, and sales, serving both retail partners and consumers worldwide.
Core Business
Perrigo operates through three primary business segments, generating approximately $5 billion in annual revenue with a 4.5% year-over-year growth rate. The Nutritional Supplements segment represents the largest portion of revenue at 40%, encompassing vitamins, minerals, and herbal supplements, with annual revenue approaching $2 billion and growth of 4.2%. The company produces over 120 new products annually and invests more than 3% of revenue into research and development, maintaining five dedicated R&D centers staffed by approximately 800 research personnel.
The Infant Nutrition segment contributes 25% of total revenue, or approximately $1.25 billion, and represents the company's fastest-growing division with expansion of 5.5% annually. This segment includes infant formula and baby food products that meet pharmaceutical-grade quality standards with cGMP compliance. The Health Products segment rounds out the portfolio at 35% of revenue, or $1.75 billion, covering meal replacements, functional foods, medical nutrition, and OTC personal care products with growth of 4.8%. Operating profit reached approximately $700 million in 2024, representing a 5.2% increase, while net income rose to $450 million.
Global Presence
Perrigo maintains significant global reach through its network of 15 manufacturing facilities and operations spanning more than 40 countries. North America serves as the dominant market, contributing 70% of total revenue with stable growth of 4.0%. Europe represents 20% of revenue with robust expansion at 5.5%, while emerging markets across Asia, Australia, and Latin America contribute 10% of revenue but demonstrate the highest growth potential at 8.2%. The company operates at considerable manufacturing scale with annual capacity exceeding 500,000 metric tons, enabling industry-leading cost control capabilities and superior value delivery to retail partners.
Key Strengths
Perrigo's competitive positioning rests on its distinctive own-brand business model partnering with major global retailers, pharmaceutical-grade quality standards, and significant manufacturing scale. The company's investment in innovation, with 120+ new product launches annually, combined with operational efficiency gains that improved gross margins by 50 basis points to approximately 40%, ensures continued strength in the competitive health products marketplace. Sustainability initiatives targeting 10% carbon intensity reduction and 20% waste reduction further reinforce the company's commitment to responsible operations and long-term strategic positioning.
